US Patent Issued to ALX ONCOLOGY on Jan. 20 for "Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPAlpha for treating gastric or gastroesphageal junction cancel" (California Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,527,838, issued on Jan. 20, was assigned to ALX ONCOLOGY INC. (South San Francisco, Calif.).

"Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPAlpha for treating gastric or gastroesphageal junction cancel" was invented by Hong Wan (Foster City, Calif.), Bang Janet Sim (South San Francisco, Calif.), Sophia Randolph (Chico, Calif.), Jaume Pons (San Francisco) and Tracy Chia-Chien Kuo (San Carlos, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are methods of treating cancer that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPAlpha D1 domain variant and an Fc do...